Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% during the third quarter, HoldingsChannel.com reports. The firm owned 93,388 shares of the biopharmaceutical company’s stock after selling 5,779 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Gilead Sciences were worth $7,830,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of GILD. TT International Asset Management LTD bought a new stake in Gilead Sciences in the third quarter valued at about $1,257,000. Coldstream Capital Management Inc. grew its position in shares of Gilead Sciences by 9.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 22,882 shares of the biopharmaceutical company’s stock worth $1,932,000 after acquiring an additional 2,043 shares in the last quarter. Gould Capital LLC increased its holdings in shares of Gilead Sciences by 22.2% in the 3rd quarter. Gould Capital LLC now owns 16,128 shares of the biopharmaceutical company’s stock valued at $1,352,000 after acquiring an additional 2,927 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after acquiring an additional 574,421 shares in the last quarter. Finally, Brophy Wealth Management LLC bought a new position in Gilead Sciences during the third quarter worth $1,275,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $92.38 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock has a 50-day simple moving average of $89.65 and a 200 day simple moving average of $79.17. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The stock has a market capitalization of $115.13 billion, a P/E ratio of 1,026.44, a P/E/G ratio of 2.86 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the firm posted $2.29 EPS. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.37 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.33%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 447,234 shares of company stock worth $41,288,086. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Bank of America reissued a “buy” rating and set a $109.00 target price on shares of Gilead Sciences in a report on Tuesday. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Truist Financial lifted their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Sanford C. Bernstein started coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday. Twelve equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.